MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial-Reference-Cited by-同舟云学术

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

Published:2013-05-16 Issue:20 Volume:121 Page:4056-4062
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zhu Hong-Hu¹,Zhang Xiao-Hui¹,Qin Ya-Zhen¹,Liu Dai-Hong¹,Jiang Hao¹,Chen Huan¹,Jiang Qian¹,Xu Lan-Ping¹,Lu Jin¹,Han Wei¹,Bao Li¹,Wang Yu¹,Chen Yu-Hong¹,Wang Jing-Zhi¹,Wang Feng-Rong¹,Lai Yue-Yun¹,Chai Jun-Yue²,Wang Li-Ru³,Liu Yan-Rong¹,Liu Kai-Yan¹,Jiang Bin¹,Huang Xiao-Jun¹⁴

Affiliation:

1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China;

2. Beijing No.6 Hospital, Beijing, China;

3. Beijing Rehabilitation Hospital, Beijing, China; and

4. Peking-Tsinghua Center for Life Sciences, Beijing, China

Abstract

Key Points Risk stratification treatment of t(8;21) acute myeloid leukemia may decrease relapse and improve long-term survival. Allo-HSCT benefited high-risk patients, but impaired the survival of low-risk patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/20/4056/530955/4056.pdf

Reference30 articles.

1. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial.;Grimwade;Blood,1998

2. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.;Byrd;J Clin Oncol,1999

3. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.;Nguyen;Blood,2002

4. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.;Schlenk;J Clin Oncol,2004

5. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.;Marcucci;J Clin Oncol,2005

Cited by 257 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT;Bone Marrow Transplantation;2024-08-02

2. Allogeneic transplantation for AML with RUNX1::RUNX1T1 fusion: a time-dependent analysis in a retrospective study;2024-07-12

3. Comparison of allo-SCT, auto-SCT and chemotherapy for the treatment of patients with low- or intermediate-risk acute myeloid leukemia: a network meta-analysis;Stem Cell Research & Therapy;2024-05-31

4. Prognostic Factors of Pediatric Acute Myeloid Leukemia Patients with t(8;21) (q22;q22): A Single-Center Retrospective Study;Children;2024-05-17

5. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia;Advances in Oncology;2024-05